Notification
No new Notification messages
Zinka Logistics Solutions IPO is Open!
Apply for the Zinka Logistics Solutions IPO through UPI in just minutes.
Q2 FY'24-25 Results of Top Companies
Reliance, TCS, HDFC Bank & more: Explore key financial highlights from India's top quarterly results.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
NSE BSE
orchid pharma limited stock

ORCHID PHARMA LIMITED Share Price

1477.6 36.69 (2.54%)
Nov 21 2024 03:30 PM Pharmaceuticals NSE: ORCHPHARMA

ORCHID PHARMA LIMITED Share Price Update

As of the latest trading session, ORCHID PHARMA LIMITED share price is currently at 1477.6, which is up by 36.69 from its previous closing. Today, the stock has fluctuated between 1420.00 and 1484.00. Over the past year, ORCHID PHARMA LIMITED has achieved a return of 166.70 %. In the last month alone, the return has been 9.74 %. Read More...

ORCHID PHARMA LIMITED Performance

Day Range

Low1420.00 High1484.00
1477.60

52 Week Range

Low 523.85 High 1590.00
1477.60

ORCHID PHARMA LIMITED Share Price

926

524372

ORCHPHARMA

img img img img
No Data Available

Open Price

1440.00

Prev. Close

1440.90

Volume (Shares)

64123.00

Total traded value

947.48

Upper Circuit

1729.05

Lower Circuit

1152.75

Note: The current prices & values are delayed, Login to your account for live updates.

ORCHID PHARMA LIMITED Fundamentals


(Standalone)

Market Cap (Cr) 7494.25
PE Ratio (TTM) 63.06
Book Value / Share 250.68
Beta 0.70
ROE 3.15%
EPS (TTM) 23.36
Dividend Yield 0.00%
Net Profit Qtr (Cr) 25.63

ORCHID PHARMA LIMITED Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition

Revenue

Net income

Particulars SEP 2024 (Values in Cr)
Revenue 222.70
Operating Expense 205.04
Net Profit 25.63
Net Profit Margin (%) 11.50
Earnings Per Share (EPS) 5.05
EBITDA 37.56
Effective Tax Rate (%) 0.00
Particulars JUN 2024 (Values in Cr)
Revenue 244.41
Operating Expense 223.07
Net Profit 29.10
Net Profit Margin (%) 11.90
Earnings Per Share (EPS) 5.74
EBITDA 41.01
Effective Tax Rate (%) 0.00
Particulars MAR 2024 (Values in Cr)
Revenue 217.10
Operating Expense 200.03
Net Profit 33.19
Net Profit Margin (%) 15.28
Earnings Per Share (EPS) 6.86
EBITDA 41.81
Effective Tax Rate (%) -10.78
Particulars DEC 2023 (Values in Cr)
Revenue 220.59
Operating Expense 197.48
Net Profit 30.55
Net Profit Margin (%) 13.84
Earnings Per Share (EPS) 6.42
EBITDA 43.36
Effective Tax Rate (%) 0.00
Particulars SEP 2023 (Values in Cr)
Revenue 198.76
Operating Expense 186.70
Net Profit 20.24
Net Profit Margin (%) 10.18
Earnings Per Share (EPS) 4.40
EBITDA 31.88
Effective Tax Rate (%) 0.00
Particulars MAR 2024 (Values in Cr)
Revenue 819.37
Operating Expense 758.24
Net Profit 94.75
Net Profit Margin (%) 11.56
Earnings Per Share (EPS) 19.59
EBITDA 141.07
Effective Tax Rate (%) -3.52
Particulars MAR 2023 (Values in Cr)
Revenue 665.90
Operating Expense 669.30
Net Profit 54.19
Net Profit Margin (%) 8.13
Earnings Per Share (EPS) 13.28
EBITDA 142.26
Effective Tax Rate (%) 0.00
Particulars MAR 2022 (Values in Cr)
Revenue 556.97
Operating Expense 618.75
Net Profit -4.81
Net Profit Margin (%) -0.86
Earnings Per Share (EPS) -1.18
EBITDA 66.25
Effective Tax Rate (%) 0.00
Particulars MAR 2021 (Values in Cr)
Revenue 450.70
Operating Expense 553.03
Net Profit -117.15
Net Profit Margin (%) -25.99
Earnings Per Share (EPS) -28.70
EBITDA 64.37
Effective Tax Rate (%) 0.00
Particulars MAR 2020 (Values in Cr)
Revenue 481.21
Operating Expense 593.94
Net Profit -149.84
Net Profit Margin (%) -31.13
Earnings Per Share (EPS) -16.87
EBITDA 33.61
Effective Tax Rate (%) 0.00
Particulars MAR 2024 (Values in Cr)
Book Value / Share 217.06
ROE % 3.02
ROCE % 3.20
Total Debt to Total Equity 0.25
EBITDA Margin 17.32
Particulars MAR 2023 (Values in Cr)
Book Value / Share 151.92
ROE % 0.29
ROCE % 1.47
Total Debt to Total Equity 0.45
EBITDA Margin 15.46
Particulars MAR 2022 (Values in Cr)
Book Value / Share 141.81
ROE % 0.06
ROCE % -1.10
Total Debt to Total Equity 0.55
EBITDA Margin 11.27
Particulars MAR 2021 (Values in Cr)
Book Value / Share 143.16
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.72
EBITDA Margin 9.91
Particulars MAR 2020 (Values in Cr)
Book Value / Share 187.67
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 61.28
EBITDA Margin -1.43
Particulars MAR 2024 (Values in Cr)
Book Value / Share 226.69
ROE % 3.15
ROCE % 3.33
Total Debt to Total Equity 0.24
EBITDA Margin 17.26
Particulars MAR 2023 (Values in Cr)
Book Value / Share 162.53
ROE % 0.81
ROCE % 2.34
Total Debt to Total Equity 0.43
EBITDA Margin 15.46
Particulars MAR 2022 (Values in Cr)
Book Value / Share 149.30
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.53
EBITDA Margin 12.06
Particulars MAR 2021 (Values in Cr)
Book Value / Share 150.13
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.69
EBITDA Margin 9.75
Particulars MAR 2020 (Values in Cr)
Book Value / Share 178.67
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 88.62
EBITDA Margin -5.34
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 266.56
Total Assets 1553.87
Total Liabilities 1553.87
Total Equity 1169.46
Share Outstanding 50719105
Price to Book Ratio 4.61
Return on Assets (%) 5.93
Return on Capital (%) 7.07
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 30.62
Total Assets 1225.20
Total Liabilities 1225.20
Total Equity 688.64
Share Outstanding 40816400
Price to Book Ratio 2.37
Return on Assets (%) 3.78
Return on Capital (%) 4.54
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 8.06
Total Assets 1110.56
Total Liabilities 1110.56
Total Equity 647.37
Share Outstanding 40816400
Price to Book Ratio 1.90
Return on Assets (%) -0.17
Return on Capital (%) -0.21
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 19.91
Total Assets 1237.25
Total Liabilities 1237.25
Total Equity 652.90
Share Outstanding 40816400
Price to Book Ratio 16.42
Return on Assets (%) -9.41
Return on Capital (%) -10.76
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 174.04
Total Assets 1459.90
Total Liabilities 1459.90
Total Equity 765.98
Share Outstanding 40816400
Price to Book Ratio 0.00
Return on Assets (%) -8.97
Return on Capital (%) -10.32
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 257.22
Total Assets 1552.20
Total Liabilities 1552.20
Total Equity 1218.31
Share Outstanding 50719105
Price to Book Ratio 4.61
Return on Assets (%) 6.10
Return on Capital (%) 7.01
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 22.33
Total Assets 1223.25
Total Liabilities 1223.25
Total Equity 731.96
Share Outstanding 40816400
Price to Book Ratio 2.37
Return on Assets (%) 4.42
Return on Capital (%) 5.1
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 4.20
Total Assets 1094.18
Total Liabilities 1094.18
Total Equity 677.95
Share Outstanding 40816400
Price to Book Ratio 1.90
Return on Assets (%) -0.43
Return on Capital (%) -0.51
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 18.96
Total Assets 1224.46
Total Liabilities 1224.46
Total Equity 681.33
Share Outstanding 40816400
Price to Book Ratio 16.42
Return on Assets (%) -9.56
Return on Capital (%) -10.33
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 172.31
Total Assets 1449.99
Total Liabilities 1449.99
Total Equity 797.82
Share Outstanding 40816400
Price to Book Ratio 0.00
Return on Assets (%) -10.33
Return on Capital (%) -11.51
Particulars MAR 2024 (Values in Cr)
Net Income 89.04
Cash from Operations 125.36
Cash from Investing -312.02
Cash from Financing 167.04
Net change in Cash -18.99
Free Cash Flow 190.17
Particulars MAR 2023 (Values in Cr)
Net Income 46.31
Cash from Operations 18.63
Cash from Investing -31.21
Cash from Financing 31.16
Net change in Cash 18.29
Free Cash Flow 103.54
Particulars MAR 2022 (Values in Cr)
Net Income -1.95
Cash from Operations 94.38
Cash from Investing 112.93
Cash from Financing -216.79
Net change in Cash -11.38
Free Cash Flow 108.78
Particulars MAR 2021 (Values in Cr)
Net Income -116.53
Cash from Operations 18.66
Cash from Investing 67.20
Cash from Financing -164.98
Net change in Cash -74.19
Free Cash Flow 19.26
Particulars MAR 2020 (Values in Cr)
Net Income -131.07
Cash from Operations 70.38
Cash from Investing 167.11
Cash from Financing -250.33
Net change in Cash -2.41
Free Cash Flow 74.62
Particulars MAR 2024 (Values in Cr)
Net Income 91.52
Cash from Operations 129.99
Cash from Investing -315.80
Cash from Financing 167.06
Net change in Cash -18.01
Free Cash Flow 185.14
Particulars MAR 2023 (Values in Cr)
Net Income 54.18
Cash from Operations 13.68
Cash from Investing -26.69
Cash from Financing 31.16
Net change in Cash 17.85
Free Cash Flow 98.24
Particulars MAR 2022 (Values in Cr)
Net Income -4.80
Cash from Operations 91.47
Cash from Investing 112.93
Cash from Financing -216.79
Net change in Cash -14.30
Free Cash Flow 105.87
Particulars MAR 2021 (Values in Cr)
Net Income -117.15
Cash from Operations 19.44
Cash from Investing 67.20
Cash from Financing -164.98
Net change in Cash -73.42
Free Cash Flow 20.04
Particulars MAR 2020 (Values in Cr)
Net Income -149.83
Cash from Operations 69.99
Cash from Investing 167.11
Cash from Financing -250.33
Net change in Cash -2.79
Free Cash Flow 74.23
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 55.85 32.10 3.04 428.00 37.54 / 77.70
BLISS GVS PHARMA LTD 120.75 15.11 1.25 1271.52 92.25 / 148.95
CIPLA LTD 1471.35 25.74 4.18 118825.56 1165.10 / 1702.00
FERMENTA BIOTECH LIMITED 331.20 115.00 3.35 974.75 145.00 / 354.60
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 55.85 48.57 9.49 428.00 37.54 / 77.70
AMRUTAJAN HEALTH LTD 720.90 43.85 6.99 2084.17 556.05 / 861.40
ASTRAZENECA PHARMA IND LT 6497.50 126.19 23.91 16243.75 4050.15 / 8139.85
BLISS GVS PHARMA LTD 120.75 15.72 1.24 1271.52 92.25 / 148.95

Technicals

  • EMA & SMA
  • Resistance and Support
  • Price Change Analysis
- redarrow -
red-green-graph indicator
Bullish Moving Averages -
Bearish Moving Averages -
  • 5 Days 1441.80
  • 26 Days 1412.00
  • 10 Days 1442.10
  • 50 Days 1410.60
  • 12 Days 1450.40
  • 100 Days 1361.20
  • 20 Days 1411.90
  • 200 Days 928.70
1442.22
PIVOT
First Resistance 1476.58
Second Resistance 1512.27
Third Resistance 1546.63
First Support 1406.53
Second Support 1372.17
Third Support 1336.48
RSI 63.13
MACD 38.34
Commodity Channel Index (CCI) 43.65
ADX 8.74
Williams % R -45.31

Over 1 Month

down

9.74

Over 3 Months

down

2.47

Over 6 Months

down

31.56

Over 1 Year

down

166.70

Over 3 Years

down

53.56

Over 5 Years

down

140.25

ORCHID PHARMA LIMITED Future

Future: Price

25 May
0 100 200 300 400 500 600

Discount/Premium

25 May
0 1 2 3 4 5 6 7

Active Calls

25 May
0 500 1000 1500 2000 2500 3000

Active Puts

25 Jul
0 500 1000 1500 2000 2500

ORCHID PHARMA LIMITED Shareholding Pattern

  • Shareholding Summary
  • Historical Promotor Holding
  • Historical MF Holding
  • Historical FII Holding

Holding

Others
11.44
Promoter Holdings
69.83
FII
1.93
DII
16.78
Promoter Shares(Pledge Percentage)
0.0
Name Category Shares Shares%
Dhanuka Laboratories Limited Shareholding of Promoter and Promoter Group 3.5419957E7 69.84
Quant Mutual Fund - Quant Small Cap Fund Public Shareholding 3465947.0 6.83
Invesco India Equity Savings Fund And 6 Others Under The Same Pan Public Shareholding 2452420.0 4.84
Nippon Life India Trustee Ltd-a/c Nippon India Pharma Fund Public Shareholding 623032.0 1.23
Jm Financial Mutual Fund- Jm Focused Fund And 6 Others Under The Same Pan Public Shareholding 584361.0 1.15

ORCHID PHARMA LIMITED

  • Dividend
  • Bonus
  • Split
Ex-Date Dividend Amt. Dividend Type Record Date Instrument Type
2012-09-13 3.0 Final 2012-09-15 Equity shares 2011-07-19 3.0 Final 2011-07-21 Equity shares 2010-07-12 10.0 Final 2010-07-14 Equity shares 2009-09-17 1.0 Final 2009-09-19 Equity shares 2008-09-18 3.0 Final 2008-09-20 Equity shares 2007-07-12 3.0 Final 2007-07-15 Equity shares 2006-05-30 0.0 Final 2006-06-01 Equity shares 2005-07-13 0.0 Interim 2005-07-15 Equity shares
Ex-Date Ex-Bonus Ratio
2005-09-17 2005-09-15 1:2
Ex-Date Old FV NEW FV Record Date

Learn More About Stocks

About ORCHID PHARMA LIMITED

Read More
  • Management structure
  • Board of directors
  • Committees of the board of directors

Companies Owned by ORCHID PHARMA LIMITED

We have something for everyone

Explore More Investment Options

Stocks

Secure and enhance your financial future today

investment-card-icon

IPOs

Your gateway to future financial opportunities

investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 4x  

investment-card-icon

US Stocks

Discover opportunities to invest in elite FAANG stocks

investment-card-icon

Frequently Asked Questions

What is the Share Price of Orchid Pharma Ltd?

Answer Field

The share price of Orchid Pharma Ltd for NSE is ₹ 1477.6 and for BSE is ₹ 1465.2.

What is the Market Cap of Orchid Pharma Ltd?

Answer Field

The market cap of Orchid Pharma Ltd for NSE is ₹ 74,94.25 Cr. and for BSE is ₹ 74,31.36 Cr. as of now.

What is the 52 Week High and Low of Orchid Pharma Ltd?

Answer Field

The 52 Week High and Low of Orchid Pharma Ltd for NSE is ₹ 1590.00 and ₹ 523.85 and for BSE is ₹ 1591.55 and ₹ 529.95.

How to Buy Orchid Pharma Ltd share?

Answer Field

You can trade in Orchid Pharma Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Orchid Pharma Ltd?

Answer Field

The 1 year returns on the stock has been 166.70%.

What is the Current Share Price of Orchid Pharma Ltd?

Answer Field

Orchid Pharma Ltd share price is for NSE ₹ 1477.6 & for BSE ₹ 1465.2 as on Nov 21 2024 03:30 PM.

What is the Market Cap of Orchid Pharma Ltd Share?

Answer Field

The market cap of Orchid Pharma Ltd for NSE ₹ 74,94.25 & for BSE ₹ 74,31.36 as on Nov 21 2024 03:30 PM.

What is the P/E Ratio of Orchid Pharma Ltd Share?

Answer Field

As on Nov 21 2024 03:30 PM the price-to-earnings (PE) ratio for Orchid Pharma Ltd share is 63.06.

What is the PB ratio of Orchid Pharma Ltd Share?

Answer Field

As on Nov 21 2024 03:30 PM, the price-to-book (PB) ratio for Orchid Pharma Ltd share is 250.68.

How to Buy Orchid Pharma Ltd Share?

Answer Field

You can trade in Orchid Pharma Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Orchid Pharma Ltd Share on Bajaj Broking App?

Answer Field

To buy Orchid Pharma Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Orchid Pharma Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs + Users

icon-with-text

4.8+ App Rating

icon-with-text

4 Languages

icon-with-text

₹5000+ Cr MTF Book

icon-with-text
loader